We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$27M
Cap. Flow
+$16.7M
Cap. Flow %
1.92%
Top 10 Hldgs %
32.2%
Holding
103
New
12
Increased
47
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$16.5M
2
WGS icon
GeneDx Holdings
WGS
+$13.7M
3
DHR icon
Danaher
DHR
+$9.08M
4
DXCM icon
DexCom
DXCM
+$7.49M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.86M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$27.6M
2
UNH icon
UnitedHealth
UNH
+$26.3M
3
SYK icon
Stryker
SYK
+$10.2M
4
GILD icon
Gilead Sciences
GILD
+$9.29M
5
PODD icon
Insulet
PODD
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIBN icon
51
SI-BONE Inc
SIBN
$852M
$6.81M 0.78%
362,008
+130,899
+57% +$2.17M
MLYS icon
52
Mineralys Therapeutics
MLYS
$2.38B
$6.27M 0.72%
463,601
+169,673
+58% +$2.46M
QURE icon
53
uniQure
QURE
$3.13B
$6.18M 0.71%
443,422
+239,589
+118% +$3.22M
AORT icon
54
Artivion
AORT
$1.4B
$5.99M 0.69%
192,705
+81,053
+73% +$2.19M
VCYT icon
55
Veracyte
VCYT
$3.59B
$5.96M 0.68%
220,387
+54,109
+33% +$1.57M
CERT icon
56
Certara
CERT
$1.22B
$5.85M 0.67%
+500,000
New +$5.92M
ALKS icon
57
PUT
Alkermes
ALKS
$8.44B
$5.72M 0.66%
+200,000
New +$5.95M
WAY
58
Waystar Holding Corp
WAY
$4.71B
$5.72M 0.66%
+140,000
New +$5.39M
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.65B
$5.38M 0.62%
147,980
-156,264
-51% -$5.63M
INCY icon
60
Incyte
INCY
$24.5B
$5.11M 0.59%
+75,000
New +$4.75M
TMCI icon
61
Treace Medical Concepts
TMCI
$309M
$4.96M 0.57%
843,998
+130,459
+18% +$850K
RCUS icon
62
Arcus Biosciences
RCUS
$3.69B
$4.88M 0.56%
599,610
-616,019
-51% -$5.26M
PHLT
63
DELISTED
Performant Healthcare Inc
PHLT
$4.86M 0.56%
1,214,272
+153,671
+14% +$436K
XENE icon
64
Xenon Pharmaceuticals
XENE
$6.31B
$4.71M 0.54%
150,373
-24,203
-14% -$789K
CVRX icon
65
CVRx
CVRX
$72.7M
$4.64M 0.53%
789,099
-440,423
-36% -$3.04M
AMLX icon
66
Amylyx Pharmaceuticals
AMLX
$2.6B
$4.17M 0.48%
+650,000
New +$3.16M
FOLD
67
DELISTED
Amicus Therapeutics
FOLD
$3.49M 0.4%
608,637
+39,685
+7% +$256K
QTRX icon
68
Quanterix
QTRX
$139M
$3.43M 0.39%
+515,992
New +$2.88M
PTGX icon
69
Protagonist Therapeutics
PTGX
$9.84B
$3.4M 0.39%
+61,596
New +$2.96M
DAWN
70
DELISTED
Day One Biopharmaceuticals
DAWN
$3.25M 0.37%
500,000
-543,162
-52% -$3.74M
RPID icon
71
Rapid Micro Biosystems
RPID
$84.8M
$3.15M 0.36%
913,443
+177,822
+24% +$516K
TERN
72
DELISTED
Terns Pharmaceuticals
TERN
$3.05M 0.35%
817,808
-141,895
-15% -$443K
NSPR icon
73
InspireMD
NSPR
$40.3M
$2.8M 0.32%
1,235,305
+63,889
+5% +$159K
VERA icon
74
Vera Therapeutics
VERA
$2.16B
$2.74M 0.32%
116,343
+40,218
+53% +$904K
DVAX
75
DELISTED
Dynavax Technologies
DVAX
$2.68M 0.31%
270,131
+35,347
+15% +$372K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Parkman Healthcare Partners held 103 positions worth $870M, up 3.2% from $843M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q2 2025 filing shows 12 new, 47 increased, 28 reduced and 15 closed positions. Its largest new stake was IQVIA: 109,500 shares worth $17.3M. The largest sale was Becton Dickinson, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q2 2025 buy was IQVIA: 109,500 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Danaher in Q2 2025, an estimated $9.08M increase.
  • Parkman Healthcare Partners's biggest Q2 2025 reduction was Stryker, cutting an estimated $10.2M.
  • Parkman Healthcare Partners fully exited Becton Dickinson in Q2 2025, selling an estimated $27.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $870M portfolio in Q2 2025.
  • Parkman Healthcare Partners opened 12 new positions and closed 15 in Q2 2025.
  • Parkman Healthcare Partners's portfolio value rose 3.2% quarter-over-quarter to $870M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.